Overview

Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this extension study is to allow patients being treated with enteric-coated mycophenolate sodium (core study CERL080A2405LA01) to continue on the same treatment and to assess the long-term safety of EC-MPS.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis
Treatments:
Mycophenolate mofetil
Mycophenolic Acid
Criteria
Inclusion Criteria:

- All patients who completed study CERL080A2405-LA01 and who are willing to continue
treatment with Enteric-Coated Mycophenolate Sodium.

Exclusion Criteria:

- Other protocol-defined inclusion / exclusion criteria may apply